MAPT and early-onset autosomal dominant Alzheimer disease: They used an antibody which selectively binds Alzheimer’s disease (AD)-type tau and used quantitative analysis of this tau pathology to demonstrate that AD tau is the prominent type of tau present in LRRK2 mutation carriers.